神经生物标记市场报告：2030 年趋势、预测与竞争分析

神经生物标记的趋势和预测

预计到 2030 年，全球神经生物标记市场将达到约 147 亿美元，2024 年至 2030 年的复合年增长率为 11.7%。该市场的主要驱动力是液态切片的日益普及、人工智慧 (AI) 在神经生物标记开发中的使用增加以及个人化医疗需求的不断增长。全球神经生物标记市场的未来充满希望，医院/医院实验室、独立临床诊断中心和研究机构市场都有机会。

• Lucintel 预测，由于神经系统疾病的盛行率不断增加，蛋白质体学将在预测期内按类型经历最高的增长。
• 由于医院和医院实验室被认为是神经系统疾病诊断服务的主要提供者，因此最终用途类别预计将出现最高成长。
• 按地区划分，由于阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病的高盛行率以及该地区医疗保健支出的增加，北美在预测期内仍将是最大的地区。

神经生物标誌物市场的策略性成长机会

神经生物标誌物的策略性成长机会出现在多个应用领域。这些范围从技术进步到专注于改进诊断和治疗方法的技术进步，为神经系统疾病管理之外的进一步市场扩张提供了潜力。

• 阿兹海默症：阿兹海默症的盛行率不断上升，为神经生物标记的扩展开闢了主要途径。目前正在进行生物标记研究，以确定用于早期检测和监测疾病进展的新标记。诊断和追踪老年痴呆症的生物标记将改变治疗结果，并且对于控制疾病至关重要。
• 帕金森氏症神经生物标记市场的其他关键成长领域包括帕金森氏症。帕金森氏症的生物标记研究正在兴起，新的标记被发现可以监测疾病进展和治疗反应。帕金森氏症患者迫切需要更好的诊断工具和个人化治疗方案，推动了这一领域的机会。
• 多发性硬化症：多发性硬化症的生物标记是一个越来越受关注的领域。神经影像学和生物标记研究的进步正在增加多发性硬化症早期诊断和追踪的前景。开发充分反映疾病活动和进展的生物标记对于优化治疗策略和改善患者预后尤为重要。
• 中风和创伤性脑损伤：中风和创伤性脑损伤的生物标记越来越受到研究的关注，重点是早期检测和管理。能够快速识别和评估脑损伤的生物标记代表着巨大的发展和成长机会。这些生物标记能够进行早期疗育并帮助患者从中风和创伤性脑损伤的影响中恢復。
• 发炎和神经退化性疾病：发炎和神经退化性疾病的生物标记数量持续增长。与发炎过程相关的生物标记可以更好地理解和管理多发性硬化症和阿兹海默症病理状况。非常需要改进发炎和神经退化的诊断和治疗工具。

这种策略性成长机会透过培育创新的诊断和治疗方法来推动神经生物标记市场。以阿兹海默症、帕金森氏症、多发性硬化症、中风和发炎为重点，开发与个人化治疗方案相关的更好的生物标记物，以改善神经系统疾病的治疗进展正在加速。

神经生物标记市场的驱动因素与挑战

有一些影响神经生物标记市场的主要驱动因素/挑战。技术进步、经济因素和监管因素可以显着影响市场动态。 虽然驱动因素支持成长和创新，但必须克服成本、监管和技术整合挑战，才能充分发挥神经生物标记的潜力。

推动神经生物标记市场的因素包括：

• 技术进步：神经生物标记市场的成长主要受到人工智慧和神经影像等技术进步的影响。这些技术有助于提高生物标记分析的准确性和速度，从而实现神经系统疾病的准确诊断和有效管理。科技的持续创新提高了生物标记研究的力量和有效性，并改善了患者的治疗结果。
• 神经系统疾病的盛行率不断上升：推动市场成长的主要因素是阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病的盛行率不断上升。随着这些负担的增加，对先进诊断工具和生物标记以改善早期诊断和治疗的需求将会增加。这一趋势正在推动该领域的研究和发展。
• 增加研发投入：神经生物标记市场的开拓将由研发投入的增加所推动。政府机构、研究机构和私人组织正在资助新生物标记和诊断工具的开发，以实现快速创新并为神经病学的进步做出贡献。
• 关注个人化医疗：个人化医疗的趋势正在推动生物标记的发展，从而为个别患者提供针对性的治疗。基因组学和蛋白​​质组学的进步使得能够识别特定患者基因谱特有的生物标记。这些趋势继续带来更有效的治疗、更好的结果和增强的患者照护。
• 早期诊断的需求不断增长：为了应对神经系统疾病早期诊断日益增长的需求，新的生物标记正在开发中。这种关注有助于确保有效的治疗和管理，因为阿兹海默症和帕金森氏症等疾病需要及时发现。对早期诊断的日益重视加速了对能够在疾病早期识别的生物标记的研究。

神经生物标记市场的挑战包括：

• 高开发和实施成本：该市场的主要挑战之一是先进生物标誌物的高开发和实施成本。与研发、监管核准和临床试验相关的高度可变的成本限制了新型生物标记的获取并影响了市场。
• 监管和报销问题：满足新型生物标记的监管要求和报销是很困难的。冗长的监管程序和多样化的报销政策可能会减缓新诊断工具的推出并降低其可用性。解决这些问题对于成功商业化至关重要。
• 与现有系统整合：新的生物标记和诊断在与现有医疗保健系统整合时通常面临挑战。与现有系统的兼容性和互通性是成功实施的关键。先进的生物标记可以显着改善诊断工作流程，如果要充分获得好处，就必须解决这些整合问题。

目录

第一章执行摘要

第二章全球神经生物标记市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球神经生物标记市场趋势（2018-2023）与预测（2024-2030）
• 按类型：全球神经生物标记市场
  • 基因组
  • 蛋白质体
  • 代谢体学
  • 影像
  • 其他的
• 按应用：全球神经生物标记市场
  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 泛自闭症障碍
  • 其他的
• 按最终用途分類的全球神经生物标记市场
  • 医院和医院实验室
  • 独立临床诊断中心
  • 研究机构等

第四章 2018-2030年区域市场趋势及预测分析

• 按地区分類的全球神经生物标记市场
• 北美神经生物标记市场
• 欧洲神经生物标记市场
• 亚太神经生物标记市场
• 其他地区的神经生物标记市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按类型：全球神经生物标记市场成长机会
  • 按应用：全球神经生物标记市场的成长机会
  • 全球神经生物标记市场的成长机会（按最终用途划分）：
  • 按地区：全球神经生物标记市场成长机会
• 全球神经生物标记市场的新兴趋势
• 战略分析
  • 新产品开发
  • 全球神经生物标记市场的产能扩张
  • 全球神经生物标记市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业概况

• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Merck
• Johnson & Johnson Services
• BANYAN BIOMARKERS
• Myriad Genetics

Neurological Biomarker Trends and Forecast

The future of the global neurological biomarker market looks promising with opportunities in the hospital & hospital laboratory, independent clinical diagnostic center, and research organizations markets. The global neurological biomarker market is expected to reach an estimated $14.7 billion by 2030 with a CAGR of 11.7% from 2024 to 2030. The major drivers for this market are the growing adoption of liquid biopsy, increasing utilization of artificial intelligence (AI) in neurological biomarker development, and rising demand for personalized medicine.

• Lucintel forecasts that, within the type category, proteomic is expected to witness the highest growth over the forecast period due to the increasing prevalence of neurological diseases.
• Within the end-use category, hospitals and hospital laboratories will witness the highest growth as they are considered as a primary provider of diagnostic services for neurological disorders.
• In terms of regions, North America will remain the largest region over the forecast period due to the high prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, and rising healthcare expenditure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Neurological Biomarker Market

The emerging trends within the neurological biomarker market exhibit advancements in technology, concepts of personalized medicine, and increasing research studies. Each of these may collectively usher in a paradigm shift in the formulation and application of biomarkers for neurological disorders, offering more diagnostic accuracy and treatment tailored to individual needs.

• Integration of AI and Machine Learning: The integration of AI and machine learning in the analysis of neurological biomarkers may improve diagnostic precision and efficiency. AI algorithms can deeply analyze complex neuroimaging data, including data from biomarker assays, and identify patterns that can easily be overlooked in traditional techniques. This leads to more accurate and timely diagnoses, along with superior monitoring of disease progression and treatment response.
• Neuroimaging Techniques: Recent advances in neuroimaging modalities, such as high-resolution MRI and PET, enhance the ability to visualize and quantify biomarkers associated with neurological diseases. These advances provide more detailed pictures of brain structure and function, allowing for earlier identification and more precise monitoring of conditions such as Alzheimer's and multiple sclerosis.
• Personalized Medicine: The trend toward personalized medicine drives biomarker development, which will tailor treatment to the individual patient. Advances in genomics and proteomics are identifying biomarkers specific to each genetic profile for targeted therapies that are more effective. This approach, matching the patient with their unique biomarker profile, optimizes interventions while reducing adverse effects.
• Expanding Biomarker-based Clinical Trials: The acceleration in biomarker-targeted clinical trials is further speeding up the identification and validation processes of new biomarkers for neurological disorders. These studies will research new biomarkers that facilitate early disease diagnosis, monitor the course of the illness, and predict responses to various treatments. Growing investments in biomarker-related research translate into the development of novel diagnostic tools and therapeutic strategies.
• Enhanced Collaboration and Data Sharing: There is an increasing tendency toward collaborative data sharing between research institutions, healthcare providers, and technology companies. This collaborative effort enables the pooling of data and resources, accelerates biomarker discovery, and extends the development of diagnostic and therapeutic tools. Thus, this trend nurtures innovation and enhances overall efficacy in neurological biomarker research.

These emerging trends are reshaping the neurological biomarker market by improving diagnosis, extending personalized treatment options, and encouraging innovation through advanced technology coupled with collaborative research. The use of AI, improved imaging, and the concept of personalized medicine have become some of the most influential forces for change in this area, offering better management of neurological disorders.

Recent Developments in the Neurological Biomarker Market

The field of neurological disorders is experiencing significant growth, especially due to recent advancements in technological applications that have facilitated the integration of neurological biomarkers into the existing framework of diagnosis and treatment. There are three types of neurological disorder markers: proteins, genes, and imaging, which, when combined, provide key information about brain health and the progress of specific diseases. Given the trend showing an increase in neurodegenerative diseases such as Alzheimer's and Parkinson's, pattern biomarker identification will be emphasized, aimed at facilitating the early detection of diseases and personalized treatment for patients. From these changes, we expect to make great strides toward unraveling the mysteries surrounding many diverse neurological diseases and optimizing clinical management using enhanced diagnostic and therapeutic approaches.

• Discovery of Novel Biomarkers: There has been target-specific protein and metabolite detection, particularly from blood and cerebrospinal fluid samples, that have spearheaded this development through recent studies that have pinpointed and subsequently supported the existence of promising biomarkers in Alzheimer's and Parkinson's diseases. With the identification of such biomarkers, there are many advantages, such as increased diagnostic accuracy, which enables earlier intervention and improvements in disease progression, enhancing the prospects of finding new effective therapies.
• Advances in Imaging Techniques: There has been tremendous improvement in the use of advanced MRI and PET scan imaging among patients suffering from neurological disorders to detect changes. Such imaging techniques have advanced the diagnosis of these conditions as they can reveal structural and functional abnormalities of the brain even before signs or symptoms are reported. By doing so, these imaging techniques assist in the early diagnosis of diseases, enabling prompt treatment and influencing the subsequent course of treatment.
• Genomic and Epigenetic Focus: The combination of genomic and epigenetic analyses has led to a greater understanding of these mechanisms in the context of neurological disorders. Researchers identify which genetic markers are related to diseases and how those genes cause them, subsequently examining preventive measures and intervention strategies. Personalizing treatment of this nature is a significant breakthrough, allowing strategies to be tailored to match the bioinformation of an individual.
• Relationship with Microbiome: An emerging body of evidence links the gut microbiome to the brain and, consequently, to brain disorders. Changes in gut bacteria have been associated with multiple sclerosis and autism spectrum disorders. If such connections are understood, it is feasible to devise new and more effective approaches for diseases through the use of new biomarkers, alongside modulating the microbiome of the host.
• Digital Biomarkers: The advent of wearable devices and mobile health apps has offered a solution to the limitations posed by traditional biobanks, in the form of digital biomarkers that detect and record behavioral and physiological actions. Such tools permit longitudinal measurement of brain-level activity and the occurrence of disease-related symptoms, providing objective data on the course of the disease and the impact of interventions, thus increasing patient engagement and individualization of care.

Overall, these advances in neurological biomarkers bring a paradigm shift in terms of diagnosis and therapeutic interventions in neurological disorders. Thanks to novel biomarker capabilities and technologies, as well as genomic, microbiome, and digital advances, these innovations will facilitate early recognition, optimize patient care through personalized therapy, and enhance the treatment of neurological disorders in patients.

Strategic Growth Opportunities for Neurological Biomarker Market

Strategic growth opportunities in neurological biomarkers will emerge across several applications. These range from technological advancements to a focus on improving diagnostic and therapeutic approaches, offering the potential for further market expansion as well as the management of neurological disorders.

• Alzheimer's Disease: The rise in the prevalence of Alzheimer's disease creates a significant avenue for the expansion of neurological biomarkers. Biomarker research is ongoing, with the identification of novel markers currently underway for early detection of the disease and monitoring its progression. Biomarkers that diagnose and track Alzheimer's will be integral in changing treatment outcomes and managing the disease.
• Parkinson's Disease: Other key growth areas of the neurological biomarkers market include Parkinson's disease. Biomarker studies in Parkinson's are on the rise, with new markers being found for monitoring disease progression and treatment response. This area of opportunity is driven by the pressing need for better diagnostic tools and personalized treatment options for patients with Parkinson's.
• Multiple Sclerosis: Biomarkers for MS are a field of growing interest. Improved neuroimaging and biomarker studies enhance the prospects for early diagnosis and follow-up of MS. The development of biomarkers that adequately reflect disease activity and progression is particularly important to optimize treatment strategies and improve patient outcomes.
• Stroke and Traumatic Brain Injury: Biomarkers for stroke and traumatic brain injury are gaining interest as research focuses on early identification and management. Biomarkers that can quickly identify and assess brain injury represent a tremendous development and growth opportunity. These biomarkers will enable early interventions and help patients recover from the impacts of stroke and TBI.
• Neuroinflammation and Neurodegenerative Diseases: The number of biomarkers for neuroinflammation and neurodegenerative diseases continues to increase. Biomarkers associated with neuroinflammatory processes allow for better understanding and management of conditions such as multiple sclerosis and Alzheimer's disease. There is a large need for improved diagnostic and therapeutic tools in neuroinflammation and neurodegeneration.

These strategic growth opportunities drive the neurological biomarkers market by encouraging innovative diagnostics and therapeutic approaches. The high emphasis on Alzheimer's, Parkinson's, multiple sclerosis, stroke, and neuroinflammation is fostering advancements toward developing better biomarkers associated with personalized treatment options, with a view to improving neurological disorder management.

Neurological Biomarker Market Driver and Challenges

There are a few key drivers and challenges that impact the neurological biomarker market. Technological advancements, economic factors, and regulatory considerations can significantly affect market dynamics. While the drivers support growth and innovation, challenges related to cost, regulation, and technology integration must be overcome to fully realize the potential of neurological biomarkers.

The factors responsible for driving the neurological biomarker market include:

• Technological Advancements: The growth of the neurological biomarker market is primarily influenced by technological advances such as AI and neuroimaging. These technologies have contributed to increased precision and speed in biomarker analyses, leading to accurate diagnoses and effective management of neurological disorders. Continuous innovation in technology enhances the capability and effectiveness of biomarker research, improving patient outcomes.
• Increasing Prevalence of Neurological Disorders: The primary factor contributing to market growth is the rising prevalence of neurological disorders such as Alzheimer's, Parkinson's disease, and multiple sclerosis. As these burdens increase, there will be a greater demand for advanced diagnostic tools and biomarkers that improve early diagnosis and treatment. This trend drives research and development in the field.
• Increasing Research and Development Investment: Growth in the neurological biomarker market is fueled by increased investment in research and development. Government agencies, research institutions, and private organizations are funding the development of new biomarkers and diagnostic tools, enabling quicker innovation and contributing to advancements in neurology.
• Focus on Personalized Medicine: The trend toward personalized medicine is driving the development of biomarkers that can target treatments to individual patients. Advances in genomics and proteomics are making it possible to identify biomarkers unique to a particular patient's genetic profile. These trends continue to result in more effective therapies, better treatment outcomes, and enhanced patient care.
• Increased Demand for Early Diagnosis: New biomarkers are being developed in response to the growing demand for early diagnosis of neurological disorders. Since conditions like Alzheimer's and Parkinson's require timely detection, this focus helps ensure effective treatment and management. The emphasis on early diagnosis has accelerated research into biomarkers that can identify diseases in their early stages.

Challenges in the neurological biomarker market include:

• High Development and Implementation Costs: One of the major challenges in the market is the high development and implementation costs of advanced biomarkers. The costs associated with research and development, regulatory approval, and clinical trials can vary significantly, restricting the accessibility of new biomarkers and thus affecting the market.
• Regulatory and Reimbursement Issues: Navigating regulatory requirements and reimbursement for new biomarkers can be difficult. Long regulatory procedures and diverse reimbursement policies may delay the introduction of new diagnostic tools, reducing availability. Addressing these issues is essential for successful commercialization.
• Integration with Existing Systems: New biomarkers and diagnostics often face difficulties integrating with existing healthcare systems. Compatibility and interoperability with previously established systems are key to successful implementation. These integration issues must be resolved for the full benefits of advanced biomarkers to be realized, significantly improving diagnostic workflows.

The drivers and challenges that influence the neurological biomarker market highlight the complexity of emerging technologies, cost and regulatory issues, and market access. While technological advancements and increased investment spur growth, various challenges related to technology, regulation, and integration impede the full realization of neurological biomarkers and their value addition to patient care.

List of Neurological Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neurological biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neurological biomarker companies profiled in this report include-

• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Merck
• Johnson & Johnson Services
• BANYAN BIOMARKERS
• Myriad Genetics

Neurological Biomarker by Segment

The study includes a forecast for the global neurological biomarker by type, application, end use, and region.

Neurological Biomarker Market by Type [Analysis by Value from 2018 to 2030]:

• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

Neurological Biomarker Market by Application [Analysis by Value from 2018 to 2030]:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

Neurological Biomarker Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospital & Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Research Organizations
• Others

Neurological Biomarker Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neurological Biomarker Market

The neurological biomarkers market has been undergoing significant changes in recent times, driven by technological innovations and a growing focus on precision medicine. These developments enhance diagnosis and management capabilities for neurological disorders. Established markets such as the United States, China, Germany, India, and Japan have witnessed key research, diagnostics, and treatments.

• United States: In the US, the latest developments in the neurological biomarker market focus on neuroimaging and genetic analysis. Biomarker identification has become more accurate with the integration of AI and machine learning, offering more precise diagnoses and monitoring of neurological diseases. Additionally, there has been a significant influx of clinical trials related to biomarkers for neurodegenerative diseases such as Alzheimer's and Parkinson's, aimed at validating new biomarkers and therapeutic targets.
• China: In China, growth in the neurological biomarker market is driven by the increasing demand for R&D investment. The country is currently focusing on new biomarkers to enable early-stage diagnosis and personalized treatment of neurological disorders. Various researchers in Chinese institutions and international companies are collaborating to accelerate the development of new diagnostic tools and biomarkers. Furthermore, the penetration of healthcare infrastructure facilitates wider access to advanced diagnostic technologies.
• Germany: Germany is uniquely positioned at the forefront of technological advancements in neurological biomarker research. The country excels in high-resolution neuroimaging, allowing for the quantification and identification of biomarkers for personalized medicine. German institutions lead studies to identify and validate biomarkers for several neurological disorders, such as Alzheimer's disease and multiple sclerosis. These advancements enhance diagnostic precision and permit more targeted treatments.
• India: In India, the neurological biomarker market is creating opportunities for the diagnosis of neurological diseases. The adoption of advanced neuroimaging technologies and biomarker studies is increasing in the country. Improved healthcare infrastructure and availability of diagnostic tools accelerate these initiatives. Collaborative research is also believed to be a factor that aids in the discovery of new biomarkers relevant to the Indian population.
• Japan: Japan has exhibited significant growth in the neurological biomarker market, especially concerning biomarkers for neurodegenerative diseases. Recent developments include the use of advanced neuroimaging and biomarker assays to enhance early diagnosis and disease monitoring. Japanese research institutions have also begun exploring new biomarkers related to cognitive disorders and neuroinflammation to facilitate better and more personalized treatment approaches.

Features of the Global Neurological Biomarker Market

Market Size Estimates: Neurological biomarker market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neurological biomarker market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Neurological biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the neurological biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neurological biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neurological biomarker market by type (genomic, proteomic, metabolomic, imaging, and others), application (alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorder, and others), end use (hospital & hospital laboratories, independent clinical diagnostic centers, and research organizations and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Neurological Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Neurological Biomarker Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Neurological Biomarker Market by Type
  • 3.3.1: Genomic
  • 3.3.2: Proteomic
  • 3.3.3: Metabolomic
  • 3.3.4: Imaging
  • 3.3.5: Others
• 3.4: Global Neurological Biomarker Market by Application
  • 3.4.1: Alzheimer's Disease
  • 3.4.2: Parkinson's Disease
  • 3.4.3: Multiple Sclerosis
  • 3.4.4: Autism Spectrum Disorder
  • 3.4.5: Others
• 3.5: Global Neurological Biomarker Market by End Use
  • 3.5.1: Hospital & Hospital Laboratories
  • 3.5.2: Independent Clinical Diagnostic Centers
  • 3.5.3: Research Organizations and Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Neurological Biomarker Market by Region
• 4.2: North American Neurological Biomarker Market
  • 4.2.1: North American Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.2.2: North American Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others
• 4.3: European Neurological Biomarker Market
  • 4.3.1: European Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.3.2: European Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others
• 4.4: APAC Neurological Biomarker Market
  • 4.4.1: APAC Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.4.2: APAC Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others
• 4.5: ROW Neurological Biomarker Market
  • 4.5.1: ROW Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.5.2: ROW Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Neurological Biomarker Market by Type
  • 6.1.2: Growth Opportunities for the Global Neurological Biomarker Market by Application
  • 6.1.3: Growth Opportunities for the Global Neurological Biomarker Market by End Use
  • 6.1.4: Growth Opportunities for the Global Neurological Biomarker Market by Region
• 6.2: Emerging Trends in the Global Neurological Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Neurological Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neurological Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Thermo Fisher Scientific
• 7.3: Bio-Rad Laboratories
• 7.4: Merck
• 7.5: Johnson & Johnson Services
• 7.6: BANYAN BIOMARKERS
• 7.7: Myriad Genetics